- Trials with a EudraCT protocol (56)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (2)
56 result(s) found for: Synthase.
Displaying page 1 of 3.
EudraCT Number: 2006-000136-27 | Sponsor Protocol Number: CCD02 | Start Date*: 2008-03-17 | |||||||||||||||||||||
Sponsor Name:Cytonet GmbH & Co KG | |||||||||||||||||||||||
Full Title: Open, Prospective, Uncontrolled, Multicentre Study to Evaluate The Safety and Efficacy of Multiple Applications of Liver Cell Suspension Into The Portal Vein in Children with Urea Cycle Disorders (... | |||||||||||||||||||||||
Medical condition: Neonates and Infants up to 3 months including with prenatally or postnatally confirmed urea cycle disorder with below listed deficiency and children aged > 3 months up to 5 years including with con... | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Newborns, Infants and toddlers, Children, Under 18 | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: DE (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2019-004791-19 | Sponsor Protocol Number: CACN00177-100D | Start Date*: 2020-05-11 | |||||||||||
Sponsor Name:Aeglea Biotherapeutics, Inc. | |||||||||||||
Full Title: A Phase 1/2 Multiple Ascending-Dose Study in Subjects With Homocystinuria Due to Cystathionine β-Synthase (CBS) Deficiency to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of ACN00177 | |||||||||||||
Medical condition: Homocystinuria Due to Cystathionine β-Synthase (CBS) Deficiency | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-000217-30 | Sponsor Protocol Number: IRINOX | Start Date*: 2008-02-05 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA SENESE | |||||||||||||
Full Title: Treatment with Oxaliplatin and Irinotecan in colorectal metastatic tumors with high expression of thymidilate synthase (TS). | |||||||||||||
Medical condition: PATIENTS WITH METASTATIC COLORECTAL CANCER | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-002120-33 | Sponsor Protocol Number: HLSCS01-11 | Start Date*: 2013-12-06 | ||||||||||||||||||||||||||
Sponsor Name:AZIENDA SANITARIA OSPEDALIERA O.I.R.M. - S. ANNA | ||||||||||||||||||||||||||||
Full Title: Human Liver Stem Cells (HLSCs) in patients suffering from liver-based inborn metabolic diseases causing life-threatening neonatal onset of hyperammonemic encephalopathy | ||||||||||||||||||||||||||||
Medical condition: neonatal hyperammonemic encephalopathy associated with inborn liver metabolic diseases | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Newborns, Under 18 | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: IT (Completed) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2011-002425-21 | Sponsor Protocol Number: 11054 | Start Date*: 2012-02-10 |
Sponsor Name:University of Nottingham | ||
Full Title: Efficacy of Dehydroepiandrosterone to overcome the effect of ovarian aging | ||
Medical condition: Women having low ovarian reserve undergoing IVF/ICSI treatment | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2007-004529-57 | Sponsor Protocol Number: 06/AM/108 | Start Date*: 2008-09-08 |
Sponsor Name:Greenpark Healthcare Trust | ||
Full Title: Vascular Pleiotrophic Effects of Bisphosphonates in Post Menopausal Women with Osteoporosis: Cellular Mechanisms and Functional Consequences | ||
Medical condition: osteoporosis cardiovascular disease | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2009-015955-25 | Sponsor Protocol Number: 1/09 | Start Date*: 2010-02-01 |
Sponsor Name:University Hospital | ||
Full Title: INDIVIDUAL 5-FLUOROURACIL DOSE INDIVIDUALIZATION IN PATIENTS WITH COLORECTAL CANCER | ||
Medical condition: colorectal cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: CZ (Completed) | ||
Trial results: View results |
EudraCT Number: 2005-002313-21 | Sponsor Protocol Number: TAK-475/EC302 | Start Date*: 2005-09-29 | |||||||||||
Sponsor Name:Takeda Europe Research & Development Limited | |||||||||||||
Full Title: A placebo-controlled, double-blind, randomized study to evaluate the efficacy and safety of TAK-475 50mg and 100mg versus placebo, when co-administered with simvastatin 20mg or 40mg in subjects wit... | |||||||||||||
Medical condition: Treatment of patients with primary dyslipidaemia currently taking simvastatin 20mg or 40mg | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) FI (Completed) EE (Completed) CZ (Completed) DE (Completed) LV (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-001837-10 | Sponsor Protocol Number: PRODIGE25 | Start Date*: 2016-09-27 | |||||||||||
Sponsor Name:Fédération Francophone de Cancérologie Digestive | |||||||||||||
Full Title: PHASE II RANDOMIZED TRIAL EVALUATING AFLIBERCEPT ASSOCIATED WITH SCHEME LV5FU2 AS FIRST LINE TREATMENT OF NON-RESECTABLE METASTATIC COLORECTAL CANCERS | |||||||||||||
Medical condition: first line of treatment for metastatic colorectal cancer | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-000095-28 | Sponsor Protocol Number: H3E-MC-JMHW | Start Date*: 2017-03-02 |
Sponsor Name:Eli Lilly and Company | ||
Full Title: A Phase II Study of Pemetrexed in Children with Recurrent Malignancies | ||
Medical condition: Recurrent Malignancies (recurrent solid tumors): Target tumor types were osteosarcoma, Ewing sarcoma/peripheral PNET, rhabdomyosarcoma, neuroblastoma (measurable disease), neuroblastoma (metaiodob... | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2008-002287-33 | Sponsor Protocol Number: 07009GM-A | Start Date*: 2008-10-28 |
Sponsor Name:Belfast Health and Social Care Trust [...] | ||
Full Title: Effect of HMG-Co A reductase inhibition on endothelial dysfunction, bioavailability of tetrahydrobiopterin (BH4) and functional regulation of endothelial nitric oxide synthase (eNOS) in human heart... | ||
Medical condition: Heart failure | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2014-005363-33 | Sponsor Protocol Number: ESR-14-10048 | Start Date*: 2015-04-16 |
Sponsor Name:VU university medical center | ||
Full Title: Reducing Micro Vascular dysfunction In revascularized STEMI patients by off-target properties of ticagrelor | ||
Medical condition: ST elevation myocardial infarction (STEMI) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2020-001304-42 | Sponsor Protocol Number: 20029 | Start Date*: 2020-08-24 | ||||||||||||||||
Sponsor Name:University of Nottingham | ||||||||||||||||||
Full Title: Efficacy of Nitric Oxide in Stroke -2 | ||||||||||||||||||
Medical condition: Hyperacute stroke - both ischaemic and haemorrhage | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-004876-19 | Sponsor Protocol Number: 01-05-TL-475-021 | Start Date*: 2006-02-13 | |||||||||||
Sponsor Name:Takeda Europe R&D Centre Ltd | |||||||||||||
Full Title: A Double-Blind, Randomized Study to Evaluate the Efficacy and Safety of TAK-475 100 mg or Placebo When Co-Administered With High Dose Statin Therapy in Subjects With Primary Hypercholesterolemia | |||||||||||||
Medical condition: Treatment of patients with primary hypercholesterolemia currently taking atorvastatin (80mg), simvastatin (80mg) or rosuvastatin (40mg) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) ES (Completed) SE (Prematurely Ended) NO (Completed) FI (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-000775-34 | Sponsor Protocol Number: 01-04-TL-475-002 | Start Date*: 2004-11-17 | |||||||||||
Sponsor Name:Takeda Europe R&D Centre Ltd | |||||||||||||
Full Title: A double-blind, randomised, parallel group study to evaluate the safety, tolerability and efficacy of TAK-475 alone or co-administered with atorvastatin in patients with primary dyslipidemia | |||||||||||||
Medical condition: Treatment of patients with primary dyslipidemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) LT (Completed) CZ (Completed) EE (Completed) SK (Completed) LV (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-003626-26 | Sponsor Protocol Number: 01-05-TL-475-016 | Start Date*: 2006-06-14 | |||||||||||
Sponsor Name:Takeda Europe R&D Centre Ltd | |||||||||||||
Full Title: A double-blind, placebo-controlled, randomized study to evaluate the efficacy and safety of TAK-475 or placebo when co-administered with current lipid-lowering therapy in subjects with homozygous f... | |||||||||||||
Medical condition: Treatment of primary dyslipidemia | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-000167-25 | Sponsor Protocol Number: UC-0110/1201 | Start Date*: 2012-05-29 | |||||||||||
Sponsor Name:UNICANCER | |||||||||||||
Full Title: A multicentric randomized phase II study evaluating dual targeting of the EGFR using the combination of cetuximab and afatinib versus cetuximab alone in patients with chemotherapy refractory wtKRAS... | |||||||||||||
Medical condition: Refractory wtKRAS metastatic colorectal cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-000614-21 | Sponsor Protocol Number: 7168K01 | Start Date*: 2007-08-09 | |||||||||||
Sponsor Name:Zambon Group S.p.A | |||||||||||||
Full Title: A multicentre, open-label study to evaluate the efficacy and safety of 5-MTHF administration, added on to the individual established therapy, on plasma homocysteine levels in patients with congenit... | |||||||||||||
Medical condition: homocystinuria | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) SK (Completed) HU (Completed) GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-012338-56 | Sponsor Protocol Number: VAS203/II/1/03 | Start Date*: 2009-07-10 | |||||||||||
Sponsor Name:vasopharm GmbH | |||||||||||||
Full Title: AN EXPLORATIVE PHASE IIa STUDY TO ASSESS SAFETY, TOLERABILITY, PHARMACODYNAMICS AND PHARMACOKINETICS OF VAS203 IN PATIENTS WITH MODERATE AND SEVERE TRAUMATIC BRAIN INJURY | |||||||||||||
Medical condition: Moderate and severe traumatic brain injury | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) FR (Completed) ES (Completed) AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-000919-85 | Sponsor Protocol Number: DP13C201 | Start Date*: 2020-05-14 | |||||||||||
Sponsor Name:DAMIAN Pharma AG | |||||||||||||
Full Title: DP13 – A Phase II Study in Patients with Primary Aldosteronism to Evaluate the Efficacy, Safety and Tolerability of the Aldosterone Synthase Inhibitor, DP13, over an 8-week Treatment Period | |||||||||||||
Medical condition: Primary Aldosteronism | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) IT (Ongoing) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.